Blogs

Maggie Beer Holdings (ASX: MBH) has ended its HGA strategic review, rejecting third-party bids and keeping the hampers business. The board now aims to lift thin margins, strengthen the balance sheet and build on Maggie Beer Products momentum.

Zimi (ASX: ZMM): Appoints Simon Gennari as Independent Chair to Strengthen Board Oversight

Oct 16, 2026

Zimi (ASX: ZMM) has appointed Simon Gennari as Independent Non-Executive Chair, with $50,000 of his $75,000 annual fees paid in shares at $0.004, locked in escrow until October 2027 and subject to shareholder approval in November.

South32 (ASX: S32): Portfolio Transformation, Copper and Zinc Growth, and Valuation Outlook

Oct 16, 2026

South32 is reshaping its portfolio by proposing to sell an aluminium asset, prioritising growth in copper and zinc. Stronger earnings and the Sierra Gorda and Hermosa developments support its outlook, while rising costs, execution risks and commodity volatility remain key considerations.

Liontown (ASX: LTR): Falls Below Key Support as Lithium Prices Slump and Costs Rise

Oct 15, 2026

Liontown (ASX: LTR) shares fell 5.6% to $0.68 as lithium prices slid, even after the board approved a $389 million Kathleen Valley expansion and the company reported its first underlying profit and $561 million in cash.

Glencore (ASX: GLC): How an ASX Listing Could Reshape the Copper Story and Its Valuation

Oct 15, 2026

Glencore (ASX: GLC) has joined the ASX through CDIs without raising capital, aiming to tap Australian super money and sharpen its copper valuation, while keeping Rio Tinto merger talk and a possible index entry in view.

Identifai Genetics (ASX: ID1): Lists With $10 Million to Back US Prenatal Blood Test

Oct 15, 2026

Identifai Genetics (ASX: ID1) has listed after raising A$10 million to build a prenatal test that screens selected inherited conditions from one maternal blood sample, with US validation and laboratory readiness now the company’s first priority.

Raiz Invest (ASX: RZI): Past Tax Problems Bring Regulatory Compliance Under Scrutiny

Raiz Invest (ASX: RZI) has disclosed historical tax compliance issues dating back to 2015, prompting an independent review and remediation program as the company assesses potential financial liabilities alongside positive FY2026 results and board changes.

Domino’s Pizza Enterprises (ASX: DMP): Leadership Shake-Up Puts Reset Plan in Focus

Domino’s Pizza Enterprises (ASX: DMP) has placed Australia and New Zealand operations under direct Group CEO oversight, renewed its Belgium franchise agreement and temporarily extended its France agreement as it works to advance its Reset Plan.

Alice Queen (ASX: AQX): Drilling Success at Horn Island Puts Assays in Focus

Alice Queen (ASX: AQX) shares rose 16.7% after Stage 1 drilling at its Horn Island Gold Project found mineralisation in all 20 holes, with the first gold assays expected in about two weeks.

Brightstar Resources (ASX: BTR): Initiation of Coverage (BUY)

Brightstar is transitioning from a small-scale producer and explorer into a larger gold developer. Its main near-term value driver is the Goldfields Project, supported by forecast production exceeding 75,000oz annually expected to start from mid-2027. However, gold price fluctuations, continued losses, financing costs and execution risks remain material. Successful commissioning in 2027, disciplined cost control and Sandstone's upcoming feasibility results will be critical to future valuation. We estimate a 12-month valuation target of $1.20 for BTR.

CSL (ASX: CSL): US$1.5 Billion Bond Deal and Plasma Tech Switch Shape Its Turnaround

CSL (ASX: CSL) has priced US$1.5 billion of corporate bonds to refinance debt and confirmed a Haemonetics plasma technology rollout across US centres by 2027, two moves that shape its recovery after a heavy reset year.

Orthocell (ASX: OCC): Prostate Pilot Could Add US$400 Million to Remplir’s US Market

Orthocell (ASX: OCC) reports encouraging early recovery results from a five-patient Remplir prostatectomy pilot, with no Remplir-related complications over about 12 months, and plans a larger trial to support a US push without new regulatory approvals.

Cogstate (ASX: CGS): Mood Disorder Trial Wins Build a US$143.7 Million Revenue Backlog

Cogstate (ASX: CGS) opened FY27 with US$25.1 million of new sales contracts, led by five Phase 3 mood disorder trials, lifting contracted revenue to US$143.7 million and giving the company a longer, clearer runway for future earnings.

Alvo Minerals (ASX: ALV): Bluebush Progress Meets Breakout Momentum

Alvo Minerals (ASX: ALV) shares jumped over 17% on strong volume after Bluebush heavy rare earth drilling results and a $1 million placement, with an investor webinar on Palma and Bluebush due on 14 October.

Codeifai (ASX: CDE): ConnectQR Expansion Brings QR Tools Into AI Platforms

Codeifai (ASX: CDE) has expanded ConnectQR across ChatGPT, Claude and Canva, targeting broader user adoption through AI and design platforms while pursuing subscription revenue and developing quantum security and anti-counterfeiting technologies.

Vection Technologies (ASX: VR1): Retelit Deal and FY26 Results Mark Commercial Progress

Vection Technologies (ASX: VR1) has secured a A$19.5 million multi-year agreement with Retelit, alongside reporting 14% revenue growth, higher adjusted EBITDA and its first positive operating cash flow as it expands across international markets.

CurveBeam AI (ASX: CVB): HiRise Wins China Approval, Opening Path to Commercial Sales

CurveBeam AI (ASX: CVB) has secured Chinese regulatory approval for its HiRise weight-bearing CT scanner, opening a pathway to commercial sales in China, alongside plans for local manufacturing and further progress in AI-based medical imaging.

Aruma Resources (ASX: AAJ): Tillex Copper Drilling Gets Funded as Share Count Doubles

Aruma Resources (ASX: AAJ) has issued 708 million shares at 0.45 cents, completing a placement tranche worth about $3.2 million. The cash backs drilling at its Tillex copper-silver project in Ontario, while the share count roughly doubles.

Vitura Health (ASX: VIT): $685,000 Cost Cut Puts Profit Plan on Firmer Ground

Vitura Health (ASX: VIT) beat its own first-quarter expectations, with revenue up 4.8%, EBITDA lifted and operating costs cut. Management's Three Horizon Plan targets profitability, with more detail due at the November annual general meeting.

Amaero Inc. (ASX: 3DA): Strong Growth, but Profitability Remains Unproven

Amaero’s advanced manufacturing business shows strong revenue growth and a sizeable backlog, but profitability remains unproven. Significant cash burn, liquidity pressures and potential dilution warrant caution, with limited valuation upside until margins, cash generation and order conversion improve.

Janus Electric (ASX: JNS): Tesla Experience and Global Orders Put Commercialisation in Focus

Oct 12, 2026